TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17250775

Group type: EXPERIMENTAL
Intervention: Dexamphetamine (10 mg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 14667790

Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g once daily
Number of subjects: 363

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam 13.5 g divided Q6H
Number of subjects: 363
Study: 11007053

Group type: EXPERIMENTAL
Intervention: Renal failure (defined as plasma creatinine > 130 μmol/1)
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Moderate renal failure, hypercalcaemia, low Bence-Jones protein excretion
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Dialysis
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Reversibility of renal failure
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Renal failure
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: High age, stage III disease, hypercalcaemia
Number of subjects: 775
Study: 8832312

Group type: EXPERIMENTAL
Intervention: Standard needle points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Needle with a protective point
Number of subjects: 0
Study: 1621656

Group type: EXPERIMENTAL
Intervention: A-DTP
Number of subjects: 316

Group type: COMPARATOR
Intervention: W-DTP
Number of subjects: 316
Study: 6391862

Group type: EXPERIMENTAL
Intervention: Single layer anastomoses
Number of subjects: 165

Group type: COMPARATOR
Intervention: Two layer anastomoses
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 165
Study: 31282325

Group type: EXPERIMENTAL
Intervention: Fatty liver disease prevalence in adults
Number of subjects: 294603

Group type: EXPERIMENTAL
Intervention: Fatty liver disease prevalence in males
Number of subjects: 294603

Group type: EXPERIMENTAL
Intervention: Fatty liver disease prevalence in females
Number of subjects: 294603

Group type: EXPERIMENTAL
Intervention: Fatty liver disease prevalence in smokers
Number of subjects: 294603

Group type: EXPERIMENTAL
Intervention: Fatty liver disease prevalence in alcohol users
Number of subjects: 294603

Group type: EXPERIMENTAL
Intervention: Fatty liver disease prevalence in patients with hypertension
Number of subjects: 294603

Group type: EXPERIMENTAL
Intervention: Fatty liver disease prevalence in patients with diabetes
Number of subjects: 294603

Group type: EXPERIMENTAL
Intervention: Fatty liver disease prevalence in patients with coronary heart disease
Number of subjects: 294603

Group type: EXPERIMENTAL
Intervention: Risk factors for fatty liver disease
Number of subjects: 294603
Study: 28328759

Group type: EXPERIMENTAL
Intervention: Topical ropivacaine (1% ropivacaine)
Number of subjects: 160
Study: 26398959

Group type: EXPERIMENTAL
Intervention: Lateral Elliptical (LE)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Standard Elliptical (SE)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Treadmill Running (TR)
Number of subjects: 16
Study: 24407915

Group type: EXPERIMENTAL
Intervention: Balance and gait training with augmented feedback (BAL)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Lower-limb strength training (CON)
Number of subjects: 51
Study: 22014897

Group type: EXPERIMENTAL
Intervention: Omitting elective nodal irradiation (ENI) during thoracic irradiation with concurrent chemo-radiotherapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Omitting ENI
Number of subjects: 38
Study: 19092550

Group type: EXPERIMENTAL
Intervention: Lifestyle program (enhanced standard care and six NP sessions)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Enhanced standard care program (one NP and one nutrition session)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Lifestyle program
Number of subjects: 58

Group type: COMPARATOR
Intervention: Enhanced standard care
Number of subjects: 58
Study: 17923032

Group type: EXPERIMENTAL
Intervention: Selective COX-2 inhibitors
Number of subjects: 5708
Study: 15059505

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (RLX) 60 mg/day for 12 months
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 11586032

Group type: EXPERIMENTAL
Intervention: Maternal intake of omega-3 fatty acids (cod-liver oil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregnancies complicated by moderate preeclampsia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 0
Study: 9638964

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 113

Group type: COMPARATOR
Intervention: Fluvastatin 20 mg
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg (after dose increase)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Fluvastatin 40 mg (after dose increase)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 113

Group type: COMPARATOR
Intervention: Fluvastatin
Number of subjects: 113
Study: 7620219

Group type: EXPERIMENTAL
Intervention: Nitroimidazoles (misonidazole, metronidazole, benznidazole, desmethylmisonidazole, etanidazole, pimonidazole, nimorazole, ornidazole, RSU 1069)
Number of subjects: 7000
Study: 2726115

Group type: EXPERIMENTAL
Intervention: Extra-amniotic saline instillation
Number of subjects: 106

Group type: COMPARATOR
Intervention: Vaginal prostaglandin E2 (3 mg)
Number of subjects: 106
Study: 31479549

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) 80 mg every 2 weeks (Q2W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) 80 mg every 4 weeks (Q4W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27453334

Group type: EXPERIMENTAL
Intervention: Post-anodal tDCS
Number of subjects: 8

Group type: COMPARATOR
Intervention: Post-sham tDCS
Number of subjects: 8
Study: 25943662

Group type: EXPERIMENTAL
Intervention: IV with oral glycerol (50% IV fluid, 50% oral fluid with added glycerol 1.5g/kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: IV (50% IV fluid, 50% oral fluid)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: oral glycerol (oral fluid with added glycerol 1.5g/kg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: oral (oral fluid only)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: IV and IV with oral glycerol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: IV with oral glycerol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: IV trials
Number of subjects: 9
Study: 24580125

Group type: EXPERIMENTAL
Intervention: Kinetic oscillation stimulation (KOS) at low frequency of the nasal mucosa
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 22553403

Group type: EXPERIMENTAL
Intervention: PEG (500 mL ingested within 2 hours starting 30 minutes after swallowing the capsule)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No additional preparation (control group A)
Number of subjects: 44
Study: 19241301

Group type: EXPERIMENTAL
Intervention: Comprehensive FP service package (individual counselling, free contraceptive materials, involvement of male partner)
Number of subjects: 2336

Group type: COMPARATOR
Intervention: Simple FP service package (limited information and referral to existing FP services)
Number of subjects: 2336
Study: 17530969

Group type: EXPERIMENTAL
Intervention: Aquatic plyometric training
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Land plyometric training
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 21
Study: 15447015

Group type: EXPERIMENTAL
Intervention: Autofluorescence spectroscopy with PCA, artificial neural networks, and red/green intensity ratios; multiple normalization techniques applied.
Number of subjects: 269
Study: 12070931

Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Delayed cholecystectomy
Number of subjects: 240
Study: 10696419

Group type: EXPERIMENTAL
Intervention: 10 mg quinine salt/kg bodyweight daily for 7 days
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 15 mg quinine salt/kg bodyweight daily for 7 days
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 20 mg quinine salt/kg bodyweight daily for 7 days
Number of subjects: 122
Study: 7647179

Group type: EXPERIMENTAL
Intervention: P300 amplitude for large digits
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Reaction time (RT) for large digits
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Frequency of errors for large digits
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: P300 amplitude for small digits
Number of subjects: 14
Study: 2286000

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (3 or 4 g per day for 2 or 3 days)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Chloramphenicol (14 days)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 76

Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 76
Study: 7027872

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 0
Study: 30632890

Group type: EXPERIMENTAL
Intervention: Enhanced counseling with visual representations of risk
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 66
Study: 28272312

Group type: EXPERIMENTAL
Intervention: Mesoglycan
Number of subjects: 0
Study: 26059981

Group type: EXPERIMENTAL
Intervention: rLH 150 IU/day administered at GnRH-ant administration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rLH 150 IU/day administered from the start of rFSH administration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rLH 75 IU/day administered at GnRH-ant administration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rLH 75 IU/day administered from the start of rFSH administration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rLH 150 IU/day administered at rFSH administration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rLH 75 IU/day administered at rFSH administration
Number of subjects: 40
Study: 24618336

Group type: COMPARATOR
Intervention: Doxorubicin (75 mg/m² by intravenous bolus on day 1 or 72 h continuous intravenous infusion)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus ifosfamide (Doxorubicin 75 mg/m²; 25 mg/m² per day, days 1-3 plus ifosfamide 10 g/m² over 4 days with mesna and pegfilgrastim)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus ifosfamide
Number of subjects: 455

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 455
Study: 22118808

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (CBT) or Escitalopram
Number of subjects: 80
Study: 19751298

Group type: EXPERIMENTAL
Intervention: T4 (Thyroxine)
Number of subjects: 1265

Group type: COMPARATOR
Intervention: Not on T4 (Control)
Number of subjects: 1265

Group type: COMPARATOR
Intervention: Not on T4 (Males)
Number of subjects: 1265

Group type: COMPARATOR
Intervention: Not on T4 (Females)
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: T4 (Females)
Number of subjects: 1265
Study: 17855198

Group type: EXPERIMENTAL
Intervention: Bilateral single-shot paravertebral blocks (BSS-PVB) with low-dose fentanyl and 3 mL bupivacaine 0.5% each (T1-7)
Number of subjects: 52

Group type: COMPARATOR
Intervention: High thoracic epidural analgesia (TEA) with bupivacaine 0.125% at 10 mL/hour
Number of subjects: 52
Study: 15064271

Group type: EXPERIMENTAL
Intervention: Desflurane (DES)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl (FEN)
Number of subjects: 40
Study: 11303715

Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 13
Study: 9255197

Group type: EXPERIMENTAL
Intervention: Potassium citrate supplementation (1.5 mmol/kg per day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Potassium citrate supplementation
Number of subjects: 39
Study: 8331334

Group type: EXPERIMENTAL
Intervention: Negative Thought Reduction (NTR)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Positive Thought Increment (PTI)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Combination of NTR and PTI
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo Treatment
Number of subjects: 86

Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 86
Study: 3554879

Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Baclofen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tizanidine and Baclofen
Number of subjects: 40
Study: 31491384

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics administered prior and subsequent to seasonal influenza vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics administered to subjects with low pre-existing antibody titers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics treatment
Number of subjects: 0
Study: 27604371

Group type: EXPERIMENTAL
Intervention: Laparoscopic dissection-based education (Group II)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both education methods (Group III)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Classroom education (Group I)
Number of subjects: 112
Study: 25887998

Group type: EXPERIMENTAL
Intervention: Unsupervised e-health supported neuromuscular training program (8-week duration) in addition to usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 23633090

Group type: EXPERIMENTAL
Intervention: Take-home emergency naloxone
Number of subjects: 5600

Group type: EXPERIMENTAL
Intervention: Treatment-as-usual plus take-home emergency naloxone
Number of subjects: 5600

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 5600
Study: 22435280

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg single IV bolus (Precalculated group, PG)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Titration of Propofol (Titration group, TG)
Number of subjects: 84
Study: 19304092

Group type: EXPERIMENTAL
Intervention: Lamellar epithelial debridement (LED)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 39
Study: 17374389

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 18415

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 18415

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 18415
Study: 15606472

Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (D/T)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 30
Study: 11528357

Group type: EXPERIMENTAL
Intervention: 0.25 mg norethindrone acetate (NA)/5 microg ethinyl estradiol (EE)
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: 1 mg norethindrone acetate (NA)/5 microg ethinyl estradiol (EE)
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: 1 mg norethindrone acetate (NA)/10 microg ethinyl estradiol (EE)
Number of subjects: 945

Group type: COMPARATOR
Intervention: 0.625 mg conjugated equine estrogens (CEE)/2.5 mg medroxyprogesterone acetate (MPA)
Number of subjects: 945
Study: 9631672

Group type: EXPERIMENTAL
Intervention: Home vaccination service
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control group (standard vaccination approach)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Home vaccination service for DTP/OPV/Hib
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control group for DTP/OPV/Hib
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Home vaccination service for MMR
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control group for MMR
Number of subjects: 405
Study: 7705552

Group type: EXPERIMENTAL
Intervention: sucralfate 2 g b.d.
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 3300310

Group type: EXPERIMENTAL
Intervention: Two doses of norfloxacin (600 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single dose of norfloxacin (800 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-dose ampicillin (3.5 g)/probenecid (1.0 g)
Number of subjects: 0
Study: 2123903

Group type: EXPERIMENTAL
Intervention: Inferior infarction with precordial ST segment depression (Group II)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Inferior infarction without precordial ST segment depression (Group III)
Number of subjects: 583
Study: 1062553

Group type: EXPERIMENTAL
Intervention: Contoured toothbrush
Number of subjects: 78

Group type: COMPARATOR
Intervention: Oral B toothbrush
Number of subjects: 78
Study: 31899198

Group type: EXPERIMENTAL
Intervention: Feeling the same or older than chronological age
Number of subjects: 533
Study: 30047786

Group type: EXPERIMENTAL
Intervention: Escitalopram (10‐20 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29246235

Group type: EXPERIMENTAL
Intervention: Nurse or Auxiliary Nurse-Midwives (ANMs)
Number of subjects: 1051

Group type: COMPARATOR
Intervention: Doctors
Number of subjects: 1051
Study: 26292291

Group type: EXPERIMENTAL
Intervention: HPV31 DNA load
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Initial viral loads
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Changes in viral loads
Number of subjects: 530
Study: 23097083

Group type: EXPERIMENTAL
Intervention: Pure delinquent group condition
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mixed group condition
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pure normative group condition
Number of subjects: 70
Study: 21716274

Group type: EXPERIMENTAL
Intervention: Clopidogrel regimen of 300 mg loading dose (LD) and 75 mg/day maintenance dose (MD) for 4 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clopidogrel regimen of 600 mg LD and 150 mg/day MD
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clopidogrel regimen of 75 mg/day MD
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clopidogrel regimen of 150 mg/day MD
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pooled analysis of CYP polymorphisms
Number of subjects: 40
Study: 19648146

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg once daily
Number of subjects: 3494

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg once daily
Number of subjects: 3494

Group type: COMPARATOR
Intervention: Enoxaparin (Control)
Number of subjects: 3494

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg and 150 mg
Number of subjects: 3494
Study: 16729745

Group type: EXPERIMENTAL
Intervention: Continuous low-volume infusion (10 cc of dye infused over 2.5 hours)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intermittent high-volume bolus infusion (10 cc bolus of dye)
Number of subjects: 21
Study: 15099614

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PANSS mania-like factor items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PANSS
Number of subjects: 0
Study: 11754859

Group type: EXPERIMENTAL
Intervention: Gentamicin-impregnated collagen fleeces (Septocoll); 3 fleeces applied locally
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (sacral drainage plus primary wound closure)
Number of subjects: 97
Study: 9243208

Group type: EXPERIMENTAL
Intervention: Cyclic conjugated oestrogens 0.3 mg/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cyclic conjugated oestrogens 0.625 mg/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cyclic conjugated oestrogens 1.25 mg/day
Number of subjects: 27
Study: 8298943

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 24
Study: 3508764

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 I.D.U.
Number of subjects: 0
Study: 30403495

Group type: EXPERIMENTAL
Intervention: Webdia app intervention for 3 months with monthly feedback and adaptation of treatment
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no app intervention)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Webdia app intervention
Number of subjects: 55
Study: 28558859

Group type: EXPERIMENTAL
Intervention: Cannabis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tobacco
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24241260

Group type: EXPERIMENTAL
Intervention: Culturally tailored pharmacist intervention
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 21347905

Group type: EXPERIMENTAL
Intervention: Experientially-primed condition
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Genetically-primed condition
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 63
Study: 18317243

Group type: EXPERIMENTAL
Intervention: Triflusal (900 mg for 18 months)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 17010858

Group type: EXPERIMENTAL
Intervention: Hydrophilic acrylic IOL (BL27, Bausch & Lomb)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hydrophobic acrylic IOL (AcrySof SA60AT, Alcon)
Number of subjects: 120
Study: 16215013

Group type: EXPERIMENTAL
Intervention: 10 mg zinc/d in cherry syrup
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cherry syrup alone (placebo)
Number of subjects: 38
Study: 10215647

Group type: EXPERIMENTAL
Intervention: MK‐966 (50 mg every day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg t.i.d.)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8845793

Group type: EXPERIMENTAL
Intervention: Prophylactic vaccination with Semliki forest virus (SFV) recombinant expressing SFV - PBj14 envelope protein
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Therapeutic vaccination with toxoid of alpha interferons
Number of subjects: 2
Study: 1706607

Group type: EXPERIMENTAL
Intervention: HIV-1 recombinant gp160 vaccine (40 or 80 micrograms)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: HIV-1 recombinant gp160 vaccine (fourth immunization)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: HIV-1 recombinant gp160 vaccine
Number of subjects: 33
Study: 389261

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 200

Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 200
Study: 30064953

Group type: EXPERIMENTAL
Intervention: ACCU-CHEK Inform II displaying 'RR LO' reading
Number of subjects: 66

Group type: COMPARATOR
Intervention: ACCU-CHEK Inform II displaying '32 mg/dL' reading
Number of subjects: 66